Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00071838
First received: October 31, 2003
Last updated: August 17, 2011
Last verified: August 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2011
  Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)